Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
bluebird bio
2
×
boston blog main
boston top stories
clinical trials
gene therapy
life sciences
national blog main
national top stories
2
×
new york blog main
san diego blog main
san francisco blog main
vertex pharmaceuticals
alnylam pharmaceuticals
ambys medicines
amicus therapeutics
ampio pharmaceuticals
angelman syndrome
astellas pharma
athenex
atlas venture
audentes therapeutics
avidity biosciences
biomarin pharmaceutical
biotech
boston
boulder/denver blog main
boulder/denver top stories
centers for medicare & medicaid services
chris collins
competitive generic therapy
cystic fibrosis
deals
detroit blog main
detroit top stories
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
fda
gout
hemophilia
What
drug
long
2
×
ago
aren’t
bio
biotechs
considering
data
developers
diseases
drugs
dyne
early
expected
experimental
eyes
fda
gene
genetic
having
help
humans
imminent
ipo
ipos
medicare
medicines
moves
muscle
news
noteworthy
patients
prices
rare
reach
road
roundup
rulings
separate
therapeutics
Language
unset
Current search:
long
×
" national top stories "
×
" bluebird bio "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
